Targeted Medical Pharma Awarded $733,429.00 in Qualifying New Therapeutic Discovery Grants

Grants Cover Theramine® , Sentra PM®, Sentra AM® and GABAdone®

Los Angeles, CA, Nov. 1, 2010 /Targeted Medical Pharma Inc. a Specialty Pharma company developing proprietary medical food products distributed through subsidiary Physician Therapeutics announced it has been awarded $733,429.00 in government grants. Under the recently enacted Patient Protection and Affordable Care Act, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed significant potential in producing new and cost-saving therapies, support job growth and increase U.S. competitiveness. Grants were awarded through a competitive application process supervised by the National Institutes of Health. All three of the Company’s applications were awarded. The first involved the reduction of gastrointestinal hemorrhage by Theramine associated with treatment of back pain syndromes. The second involves reduction of the side effects associated with sleep disorders in the elderly with Sentra PM and GABAdone, and the third addresses a safe and effective treatment for symptoms of Gulf War Illness with Sentra PM and Sentra AM. The Company will be able to expand the growth of these and other innovative products with these funds.

Download Press Release

Physician Therapeutics Clinical Trial Update

In January of 2009 Physician Therapeutics, a wholly owned subsidiary of Targeted Medical Pharma Inc.,  initiated A Double Blind randomized controlled trial of single dose Naproxen and an amino acid Medical Food Theramine for the treatment of low back pain. Using 10 national sites over a 28 day period, this study consisted of 127 patients with established back pain. The trial concluded in June of 2009, and the study will be published by the American Journal of Therapeutics in November 2010.